Literature DB >> 17437444

The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.

Michaël Peyromaure1, Philippe Camparo, Cécile Badoual, Aurélien Descazeaud, Anh-Tuan Dinh-Xuan.   

Abstract

OBJECTIVE: To analyse the prognostic value of vascular endothelial growth factor (VEGF) in men with clinically localized prostate cancer. PATIENTS AND METHODS: Paraffin wax-embedded sections from the radical prostatectomy (RP) specimens of 40 men operated for clinically localized prostate cancer were used to build tissue microarrays. Of these patients, 17 had cancer progression and bone metastases after RP (group 1), and 23 remained free-of-tumour recurrence after RP (group 2). VEGF-A expression was examined in the RP specimens using immunohistochemistry.
RESULTS: The groups had similar tumour characteristics in terms of prostate-specific antigen level, Gleason score, and pathological stage. VEGF-A expression was significantly higher in group 1 than in group 2 (P=0.046). In logistic regression analysis, VEGF-A expression was the most significant predictive factor of cancer progression after RP.
CONCLUSION: VEGF-A expression in prostate cancer tissue is associated with the risk of cancer progression after RP. These results suggest that VEGF-A expression has a prognostic impact in clinically localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437444     DOI: 10.1111/j.1464-410X.2007.06734.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  12 in total

1.  An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer.

Authors:  Brandon P Verdoorn; Changyong Feng; William A Ricke; Deepak M Sahasrabudhe; Deepak Kilari; Manish Kohli
Journal:  J Mens Health       Date:  2012-09-01       Impact factor: 0.537

2.  Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.

Authors:  A Zafeirakis
Journal:  Hippokratia       Date:  2010-07       Impact factor: 0.471

3.  Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?

Authors:  Silvan Boxler; Valentin Djonov; Thomas M Kessler; Ruslan Hlushchuk; Lucas M Bachmann; Ulrike Held; Regula Markwalder; George N Thalmann
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

4.  Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

Authors:  Tiva T VanCleave; Jason H Moore; Marnita L Benford; Guy N Brock; Ted Kalbfleisch; Richard N Baumgartner; James W Lillard; Rick A Kittles; La Creis R Kidd
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

5.  Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy.

Authors:  Eda Yirmibeşoğlu Erkal; Hüseyin Bora; Merih Tepeoğlu; Müge Akmansu
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

6.  Clinical and Genetic Predictors of Priapism in Sickle Cell Disease: Results from the Recipient Epidemiology and Donor Evaluation Study III Brazil Cohort Study.

Authors:  Mina Cintho Ozahata; Grier P Page; Yuelong Guo; João Eduardo Ferreira; Carla Luana Dinardo; Anna Bárbara F Carneiro-Proietti; Paula Loureiro; Rosimere Afonso Mota; Daniela O W Rodrigues; André Rolim Belisario; Claudia Maximo; Miriam V Flor-Park; Brian Custer; Shannon Kelly; Ester Cerdeira Sabino
Journal:  J Sex Med       Date:  2019-10-24       Impact factor: 3.802

7.  Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610.

Authors:  Larry Pan; Seunghee Baek; Pamela R Edmonds; Mack Roach; Harvey Wolkov; Satish Shah; Alan Pollack; M Elizabeth Hammond; Adam P Dicker
Journal:  Radiat Oncol       Date:  2013-04-25       Impact factor: 3.481

8.  Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α.

Authors:  Jonah R Riddell; Patricia Maier; Stephanie N Sass; Michael T Moser; Barbara A Foster; Sandra O Gollnick
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

9.  The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review).

Authors:  Weihua Chen; Kaili Mao; Zhongmin Liu; Anh Tuan Dinh-Xuan
Journal:  Oncol Lett       Date:  2014-08-21       Impact factor: 2.967

10.  Association of the serum vascular endothelial growth factor levels with benign prostate hyperplasia and prostate malignancies.

Authors:  Mohammad Reza Sharif; Amirreza Shaabani; Hossein Mahmoudi; Hassan Nikoueinejad; Hossein Akbari; Behzad Einollahi
Journal:  Nephrourol Mon       Date:  2014-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.